Chronic Lymphocytic Leukemia Research
Chronic Lymphocytic Leukemia Research is a research topic within Genetics. Science Explorer counts 54k research works in it since 1950. 13.9% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on the genomic aberrations, treatment strategies, and prognostic factors associated with chronic lymphocytic leukemia (CLL). It covers topics such as the use of BTK inhibitors (e.g., Ibrutinib), the role of rituximab, TP53 mutations, and the impact of immunoglobulin mutations. Additionally, it explores therapeutic targets and outcomes in patients with Waldenström macroglobulinemia.
- Chronic Lymphocytic Leukemia
- Genomic Aberrations
- BTK Inhibitors
- Rituximab
- Ibrutinib
- Prognostic Factors
- TP53 Mutation
- Waldenström Macroglobulinemia
- Immunoglobulin Mutation
- Therapeutic Targets
- Research works
- 54k fractional, since 1950
- In the world top 10%
- 7.5k per year above
- Top-10% rate
- 13.9% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- +17% the tick is no change
This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.
Which countries lead Chronic Lymphocytic Leukemia Research research?
By volume, the United States and China publish the most (2.9k and 1.1k works in 2022–2025).
By volume, 2022–2025
- 1 United States 2.9k works
- 2 China 1.1k works
- 3 Italy 517 works
- 4 France 388 works
- 5 India 372 works
- 6 Japan 369 works
- 7 United Kingdom 360 works
- 8 Germany 346 works
- 9 Brazil 338 works
- 10 Spain 312 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Chronic Lymphocytic Leukemia Research research?
By volume in 2022–2025, The University of Texas MD Anderson Cancer Center publishes the most Chronic Lymphocytic Leukemia Research research, followed by Dana-Farber Cancer Institute and Memorial Sloan Kettering Cancer Center.
By volume, 2022–2025
- 1 The University of Texas MD Anderson Cancer Center United States 182 works
- 2 Dana-Farber Cancer Institute United States 68 works
- 3 Memorial Sloan Kettering Cancer Center United States 53 works
- 4 Chinese Academy of Medical Sciences & Peking Union Medical College China 48 works
- 5 Mayo Clinic in Arizona United States 42 works
- 6 The Ohio State University United States 41 works
- 7 Moffitt Cancer Center United States 37 works
- 8 Harvard University United States 37 works
- 9 Mayo Clinic United States 35 works
- 10 Cleveland Clinic United States 34 works
Who are the leading researchers in Chronic Lymphocytic Leukemia Research?
The most-cited researchers publishing on Chronic Lymphocytic Leukemia Research include Kenneth J. Livak, Giuseppe Remuzzi and Gad Getz.
- 1 Kenneth J. Livak 20k citations
- 2 Giuseppe Remuzzi 8.1k citations
- 3 Gad Getz 6.2k citations
- 4 Winfried März 5.2k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is Chronic Lymphocytic Leukemia Research research done?
The largest centres of Chronic Lymphocytic Leukemia Research research in 2022–2025 are Houston (United States), Beijing (China), New York (United States) and Boston (United States). Among places with at least 20 works in it, it is an unusually large share of all research in Duarte, North Chicago and Lancaster.
Largest cities, 2022–2025
Where it is the local speciality
- DuarteUS · 22.1 works43×
- North ChicagoUS · 25.5 works31×
- LancasterUS · 22.0 works30×
Location quotient: how much more of its research is in Chronic Lymphocytic Leukemia Research than the world average.
Where is the best place to study Chronic Lymphocytic Leukemia Research?
Among universities, judged by research, Vita-Salute San Raffaele University, Medical University of Lodz and Medical College of Wisconsin score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | Vita-Salute San Raffaele University Italy | 51.9 | 18.5% | 13.9× | 16 | +26.6% |
| 2 | Medical University of Lodz Poland | 50.2 | 32.5% | 8.4× | 12 | -16.5% |
| 3 | Medical College of Wisconsin United States | 46.8 | 12.1% | 7.2× | 17 | +221.9% |
| 4 | China Pharmaceutical University China | 46.0 | 21.9% | 5.4× | 11 | +288.6% |
| 5 | Weill Cornell Medicine United States | 44.7 | 13.1% | 9.6× | 12 | — |
| 6 | Kettering University United States | 44.4 | 13.4% | 30.9× | 10 | +44.2% |
| 7 | Chinese Academy of Medical Sciences & Peking Union Medical College China | 43.0 | 11.8% | 5.4× | 48 | +103.1% |
| 8 | King Saud University Saudi Arabia | 43.0 | 21.7% | 1.5× | 12 | +257.2% |
| 9 | Medical University of Lublin Poland | 42.8 | 9.9% | 10.8× | 16 | +43.3% |
| 10 | Harvard University United States | 40.6 | 22.7% | 3.2× | 37 | -0.3% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is Chronic Lymphocytic Leukemia Research research growing?
Output in 2018–2022 was 17% higher than in 2013–2017, peaking in 2023. The fastest-growing topics are Chronic Lymphocytic Leukemia Research.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.